1.Registry System and Medical Control Program in Congenital Diseases.
Journal of the Korean Pediatric Society 1987;30(7):712-715
No abstract available.
2.A case of de Novo trisomy 12p syndrome.
Young Huuk LEE ; Kir Young KIM
Journal of the Korean Pediatric Society 1991;34(11):1581-1586
No abstract available.
Trisomy*
3.A study in The Changes of Platelet Count in iron Deficiency Anemia among Children.
Journal of the Korean Pediatric Society 1982;25(10):1015-1021
No abstract available.
Anemia, Iron-Deficiency*
;
Blood Platelets*
;
Child*
;
Humans
;
Iron*
;
Platelet Count*
4.Study on Antithyroid Antibody and Thyroid Functional Status in Patients with Turner Syndrome.
Bo Young LEE ; Duk Hi KIM ; Kir Young KIM
Journal of the Korean Pediatric Society 1989;32(10):1397-1401
No abstract available.
Humans
;
Thyroid Gland*
;
Turner Syndrome*
5.Etiological & Clinical Study for Neonatal Hepatitis & Biliary Atresia.
Ki Sub CHUNG ; Kir Young KIM ; Hyo Kyu KIM
Journal of the Korean Pediatric Society 1983;26(5):440-448
No abstract available.
Biliary Atresia*
;
Hepatitis*
6.A Clinical Study and Comprehensive Total Care in Hemophilia.
Shin Heh KANG ; Chang Hyun YANG ; Kir Young KIM
Journal of the Korean Pediatric Society 1988;31(2):202-211
No abstract available.
Hemophilia A*
7.The Response of Leukocytes in the Peripheral Blood Following Exchange Transfusion in the Newborn.
Young Mo SOHN ; Yu Young CHANG ; Young Ho KIM ; Kir Young KIM
Journal of the Korean Pediatric Society 1983;26(11):1049-1054
No abstract available.
Humans
;
Infant, Newborn*
;
Leukocytes*
8.Clinical Observation of Hemolytic Anemia in Children Except Isoimmunization.
Hak Yong KIM ; Young Mo SOHN ; Kwan Sub CHUNG ; Kir Young KIM ; Duk Jin YUN
Journal of the Korean Pediatric Society 1981;24(12):1149-1156
No abstract available.
Anemia, Hemolytic*
;
Child*
;
Humans
9.A Clinical Studies in Patients with Turner's Syndrome.
Chang Hyun YANG ; Duk Hi KIM ; Kir Young KIM ; Young Ho YANG
Journal of the Korean Pediatric Society 1987;30(10):1143-1151
No abstract available.
Humans
;
Turner Syndrome*
10.Risk Factors for Hyperglycemia in Children with Leukemia Receiving L-asparaginase.
Min Joong KWON ; Ho Seong KIM ; Kir Young KIM ; Duk Hi KIM
Journal of the Korean Pediatric Society 1994;37(6):740-745
Hyperglycemia is a well-recognized side effect of L-asparaginase in remission induction therapy of acute lymphocytic leukemia. Since hyperglycemia has preceded fatal diabetic ketoacidosis or hyperosmotic nonketotic coma in some patients, early detection and treatment of this complication are important. We determined retrospectively the risk of hyperglycemia in 117 patients with leukemia who had received L-asparaginase (& prednisolone). The results were as follows: 1) Twenty (17%) of the 117 patients developed hyperglycemia. 2) Of 47 female patients, 13 developed hyperglycemia, contrast with only 7 of 70 male patients(P<0.05). 3) All 2 obese patients developed hyperglycemia, contrast with 18 of 115 non obese patients (P<0.05). 4) Of 16 patients with a history of previous administration of L-asparaginase 6 (42%) developed hyperglycemia, contrast with only 14 (11%) of the remaining 101 patients (P<0.05). 5) Of the remaining factors analyzed-age, leukocyte counts, family history, dose of L-asparaginase-non had a statistically important influence on the development of hyperglycemia. 6) The mean glucose concentration at onset was 355+/-197.5mg/dl in patient who developed hyperglycemia with peak concentration of 404+/-253.6mg/dl. Hyperglycemia developed between 3 to 20 days after administration of L-asparaginase, and the duration of hyperglycemia was 6.90+/-5.54 days. Since hyperglycemia developed inevitably in a certain proportion of patients given L-asparaginase, we recommend blood glucose monitoring in patients with the risk factors.
Blood Glucose
;
Child*
;
Coma
;
Diabetic Ketoacidosis
;
Female
;
Glucose
;
Humans
;
Hyperglycemia*
;
Leukemia*
;
Leukocyte Count
;
Male
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Remission Induction
;
Retrospective Studies
;
Risk Factors*